1 / 6

ARNO TRIAL ( A ntithrombotic R egimens a N d O utcome)

ARNO TRIAL ( A ntithrombotic R egimens a N d O utcome). A RANDOMIZED TRIAL COMPARING BIVALIRUDIN WITH UNFRACTIONED HEPARIN IN PATIENTS UNDERGOING ELECTIVE PCI. David Antoniucci, TCT 2008, Washington DC. ARNO TRIAL.

eben
Download Presentation

ARNO TRIAL ( A ntithrombotic R egimens a N d O utcome)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ARNO TRIAL(Antithrombotic Regimens aNd Outcome) A RANDOMIZED TRIAL COMPARING BIVALIRUDIN WITH UNFRACTIONED HEPARIN IN PATIENTS UNDERGOING ELECTIVE PCI David Antoniucci, TCT 2008, Washington DC

  2. ARNO TRIAL • The aim of this randomized study is to determine if bivalirudin is still superior to unfractionated heparin plus protamine in patients undergoing elective PCI. • All patients undergoing PCI and pretreated with aspirin (325 mg), and a 600 mg loading dose of clopidogrel at least 6 hours before PCI were considered eligible for enrolment.

  3. ARNO TRIAL • TREATMENTS • Aspirin (325 mg) and clopidogrel (600 mg loading) at least 6 hours • before PCI in all patients. Abciximab on a provisional basis. • Heparin group: 100 IU per kg of body weight with or without • additional boluses to achieve an ACT of 250 to 300 seconds. Protamine 0.5 mg per 100 IU of heparin utilized. • Bivalirudin group: bolus of 0.75 mg/kg followed by infusion of • 1.75 mg/kg per hour for the duration of the procedure. • Immediate post-PCI sheath removal and routine use of closure • devices in all patients.

  4. END POINTS • Primary: in-hospital major bleeding • (REPLACE 2 definition). • Secondary: 1) 30-day composite of death, MI, TVR. • 2) 30-day net clinical outcome (death/MI/TVR or major bleeding). • 3) 30-day minor bleeding. • 4) Vascuular complications. • 5) Six-month outcome. ARNO TRIAL

  5. Study 30-Day End Points Bivalirudin UFH Incidence (%) P = 0.004 P = 0.014 P = 0.043

  6. ARNO TRIAL CONCLUSIONS In this randomized trial of patients undergoing elective PCI and pre-treated with aspirin and clopidogrel, bivalirudin compared to unfractionated heparin plus protamine resulted in a significant reduction of major bleeding, of the composite of death, MI, TVR, and in a better net clinical outcome.

More Related